RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $350

Benzinga · 2d ago
RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and lowers the price target from $445 to $350.